DBV gets peanut allergy therapy programme back on track
Shares in DBV have shot up on phase 3 results that set up a US filing for its peanut allergy therapy. which could plug a looming hole in the market.
Newsletters and Deep Dive digital magazine
Shares in DBV have shot up on phase 3 results that set up a US filing for its peanut allergy therapy. which could plug a looming hole in the market.
Overturning decades of advice, the CDC has said it no longer recommends that all US newborns receive a hepatitis B vaccine.
Prof Jonathan Benger will take over from Dr Sam Roberts as CEO of UK reimbursement authority NICE later this week, at a critical time for the agency.
Kyverna hopes to file CAR-T therapy miv-cell for approval as the first therapy for stiff person syndrome, a rare and debilitating autoimmune disease.
A California jury has awarded $40m in damages to two women who sued Johnson & Johnson, claiming that its talc products caused ovarian cancer.
Editor's Picks
Newsletters and Deep Dive
digital magazine